Interchange Capital Partners’s 10x Genomics TXG Stock Holding History

Interchange Capital Partners’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$178K	Sell	14,575 -15,272	-51%	-$305K	0.06%	273
2025 Q4	$487K	Buy	29,847 +5,669	+23%	+$85.6K	0.09%	206
2025 Q3	$283K	Buy	24,178 +13,675	+130%	+$178K	0.06%	274
2025 Q2	$122K	Sell	10,503 -1,013	-9%	-$9.23K	0.03%	276
2025 Q1	$101K	Sell	11,516 -1,121	-9%	-$14.1K	0.03%	266
2024 Q4	$175K	Buy	12,637 +14	+0.1%	+$221	0.06%	244
2024 Q3	$285K	Buy	+12,623	New	+$261K	0.1%	205
2024 Q2	–	Sell	-5,411	Closed	-$208K	–	291
2024 Q1	$208K	Buy	+5,411	New	+$238K	0.14%	157
2022 Q1	–	Sell	-1,888	Closed	-$281K	–	176
2021 Q4	$281K	Buy	+1,888	New	+$289K	0.28%	119
2021 Q2	–	Sell	-2,116	Closed	-$450K	–	213
2021 Q1	$450K	Buy	2,116 +2,092	+8,717%	+$361K	0.24%	130
2020 Q4	$3K	Buy	+24	New	+$3.48K	﹤0.01%	1038

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Interchange Capital Partners's TXG Position: Q1 2026 in Review

Interchange Capital Partners reduced its 10x Genomics (TXG) stake by 51% in Q1 2026, selling an estimated $305K and leaving 14,575 shares worth $178K. The position accounts for 0.06% of the portfolio, ranked #273.

Interchange Capital Partners first reported a position in TXG in Q4 2020 and has held it in 11 quarters since. The position peaked at $487K in Q4 2025. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

Interchange Capital Partners held 14,575 shares of 10x Genomics worth $178K as of Q1 2026.
Interchange Capital Partners sold 15,272 10x Genomics shares in Q1 2026, an estimated $305K.
10x Genomics made up 0.06% of Interchange Capital Partners's portfolio in Q1 2026, its #273 holding.
Interchange Capital Partners first reported a position in 10x Genomics in Q4 2020 and has held it in 11 quarters since.
Interchange Capital Partners's 10x Genomics position peaked at $487K in Q4 2025.
329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Interchange Capital Partners's 13F filing for Q1 2026, filed 24 Apr 2026.